Navigation Links
Paloma Pharmaceuticals to Present at the American Association for Cancer Research
Date:4/15/2008

- Presentations highlight Palomid 529 as an anti-angiogenic, anti-tumor

Akt/mTOR inhibitor -

JAMAICA PLAIN, Mass., Apr 15 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced it has presented three presentations at the 2008 annual meeting of the American Association for Cancer Research describing cancer drug Palomid 529 (P529).

P529 is a non-steroidal, synthetic, small molecule dual acting anti-angiogenic and direct anti-tumor agent created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-angiogenic agent and anti-tumor agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a TORC1/TORC2 inhibitor.

The first of the three presentations, "Palomid 529, a Dual Acting Anti-angiogenic and Direct Anti-tumor Agent Affecting the PI3K/Akt/mTor Pathway," was be given by Dr. David Sherris, President and CEO of Paloma Pharmaceuticals. The second presentation, "Palomid 529 (P529) inhibits tumor angiogenesis and selectively inhibits the Akt but not MAPK signaling pathways," was given by the laboratory of Dr. Laura E. Benjamin of the Department of Pathology and Center for Vascular Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. The last presentation, "Enhancement of radiotherapy in prostate cancer by the dibenzo[c]chrom-6-one derivative P529" was given by the laboratory of Dr. Alfonso Calvo of the Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.

"mTOR and the protein complexes mTORC1 and mTORC2 are excellent targets for cancer therapy because they provide important signaling links to tumor and stromal pathways dysregulated in many cancers," said Dr. Benjamin whose work has helped to understand the mechanism of action of P529.

"We have shown in a series of prost
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palomar and Q-MED AB Enter Into International Distribution Agreement
2. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
3. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
4. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
5. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
6. Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled Bipolar Trans Carotenoid Salts and Their Uses, for Its Family of First-In-Class Molecules
7. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
8. Microbia Announces Name Change to Ironwood Pharmaceuticals
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Memory Pharmaceuticals Receives Nasdaq Notification
11. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... February 2 , Scientists from ... the first variation in the sequence of the human genome ... variant (or SNP),was discovered by analyzing the genomes of a ... Austria, Germany and the United,States. It is located on the ...
... Repligen Corporation (Nasdaq: RGEN ) announced ... Walter C. Herlihy, Ph.D., will present at the BIO ... at 11:30 a.m. EST at the Waldorf-Astoria Hotel, 301 ... the presentation will be available via Repligen,s website at ...
... (Nasdaq: IPCM ), a leading national physician group practice company, announced today that management is scheduled to ... UBS 2009 Global Healthcare Services ... Adam Singer, M.D., Chairman and CEO, ... Jeff Taylor, President and COO, ...
Cached Biology Technology:deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor 2deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor 3deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor 4Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2IPC The Hospitalist Company, Inc. to Present at UBS 2009 Global Healthcare Services Conference 2
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... had megadroughts more extreme and widespread than any previously known ... now-lush tropical Africa was an arid scrubland during the early ... Africa and the evolution of fishes in Africa,s Great Lakes. ... the world, acts as a rain gauge," said lead scientist ...
... Indiana University environmental science professor and several colleagues suggests ... the potential to harm aquatic ecosystems. The study is ... Proceedings of the National Academies of Sciences . ... in the IU School of Public and Environmental Affairs, ...
... chicken genome or the egg genome? Researchers have answered ... of the thousands of long stretches of repeated DNA in ... The answers, published online by Nature Genetics ... the duplications in the human genome that are partly responsible ...
Cached Biology News:Newfound ancient African megadroughts may have driven the evolution of humans and fishes 2Newfound ancient African megadroughts may have driven the evolution of humans and fishes 3Newfound ancient African megadroughts may have driven the evolution of humans and fishes 4Study shows genetically engineered corn could affect aquatic ecosystems 2Study shows genetically engineered corn could affect aquatic ecosystems 3Which came first, the chicken genome or the egg genome? 2Which came first, the chicken genome or the egg genome? 3
Cell Culture Flask, 75 cm, treated polystyrene...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... In virtually every research laboratory, the ... of information accurately, inexpensively and in real ... compact lab analysis system includes the Luminex ... It utilizes xMAP technology which enables you ...
... Analysis of large numbers of samples may ... gradient system, which requires minimum operator attention. ... by PowerStream software and interface CE 4900. ... software operates in Windows XP and Windows 98 ...
Biology Products: